

BOGGO ROAD INNOVATION JUNCTION

B R I J

AUSTRALIA'S EMERGING POWERHOUSE FOR TRANSLATIONAL SCIENCE,
HARNESSING CUTTING-EDGE TECHNOLOGIES TO TURN RESEARCH INTO
REAL-WORLD SOLUTIONS FOR THE HEALTH OF PEOPLE AND PLANET

BRISBANE, AUSTRALIA

•



We acknowledge the Turrbal and Yagara people, the Traditional Owners of the land on which BRIJ sits, and commit to honouring First Nations communities as the original healers, scientists and innovators.



CONTENTS

Welcome	05
Mission	07
BRIJ highlights	08
Acknowledgement of Country	10
Why Queensland	12
Why Brisbane	14
Brisbane Knowledge Corridor	16
Why BRIJ	18
BRIJ precinct map	20
Vital statistics	22
BRIJ capabilities	24
Who we are	26
Real-world impact	30
Masterplan	38
Designed for connectivity	46
Building a legacy	48
Stewardship in action	50
How to engage	52
Contact	54
Footnotes	56



TOMORROW'S SOLUTIONS START TODAY

WELCOME

Across the globe, new ideas and technologies are transforming industries, economies and the way we live, with innovation precincts leading the charge. Boggo Road Innovation Junction (BRIJ) is primed to join this movement as the result of once-in-a-generation investment and collaborative momentum in Brisbane, Australia.

For thousands of years, this Country has been a gathering place for First Nations peoples, a place of medicine and knowledge exchange. Over the past century, the area known today as Boggo Road has evolved through many forms of healthcare and community service, each reinforcing its legacy as a place of healing and discovery. Today, the precinct brings together great thinkers whose innovations for human health and planetary wellbeing continuously inform and enrich one another.

BRIJ's establishment builds upon Queensland's robust collaborative academic ecosystem and taps into scientific networks that span the globe. What makes BRIJ truly exceptional is its fusion of intellectual creativity, nature's adaptive genius and machine intelligence – all working in concert to address our most pressing challenges. Here, clinical and biomedical sciences integrate with environmental and agricultural technologies, while emerging capabilities in quantum computing and data science accelerate discovery across sectors.

This cross-disciplinary environment sparks the unexpected connections that yield breakthroughs with the potential for global impact. Our partners – from advanced medical facilities and leading research bodies to multinational corporations and ambitious startups – work together to transform findings into life-changing diagnostics, products and treatments that benefit both people and planet.

In the coming years, this concentrated expertise will be supercharged by the state's multibillion-dollar infrastructure project, forecast to make Boggo Road the second-busiest public transport interchange in Queensland. New pedestrian links will create efficient walkable connections between BRIJ constituents, bringing more great minds together and enabling fluid collaboration at every level.

Brisbane's enviable subtropical lifestyle and competitive cost of living relative to other leading Asia-Pacific cities give elite scientific talent the freedom to think bigger. This distinctive urban setting has already attracted both blue-chip international organisations and homegrown Australian ventures since the establishment of the Ecosciences Precinct and Translational Research Institute in the early 2010s.

With our region's research excellence now well established, we have developed a strategic vision and comprehensive plan for BRIJ's future – a roadmap for creating an integrated innovation ecosystem where knowledge boundaries continuously expand and trailblazing discoveries emerge at the intersection of healthcare solutions and environmental stewardship.

We have the vision, the partners and the foundation. Now we invite you to join us. BRIJ offers a unique environment where researchers, translation experts and business leaders can be part of a community that will reshape how we understand and improve the wellbeing of our communities and the natural world.

– Prof Trent Munro
General Manager, BRIJ



MISSION

Boggo Road Innovation Junction (BRIJ) is committed to advancing human and planetary health through transformative technologies that accelerate scientific discovery and commercialisation.

Our interconnected community thrives on idea exchange, collaboration and collective progress, attracting the brightest talent from around Australia and the world to propel the next generation of breakthroughs in environmental sciences and healthcare.

BRIJ HIGHLIGHTS

BRIJ drives innovation through intentional design, strategic partnerships and world-class facilities. This summary outlines the distinct commercial advantages, cross-disciplinary capabilities and development opportunities available to current and future collaborators.



STRATEGIC LOCATION


Advantageous positioning for Asia-Pacific operations

Southern anchor of the Brisbane Knowledge Corridor – this hemisphere's largest grouping of knowledge assets

3km from Brisbane CBD

Rapid 15-minute tunnel access to Brisbane International Airport

Diverse residential options within walking distance



PLANNING FOR FUTURE GROWTH

39ha area purposefully designed to boost collaboration while creating job opportunities in high-growth sectors

100,000sqm expansion opportunity for laboratory, healthcare and commercial development

Organisations within BRIJ attract ~A\$270m in combined R&D investment annually (at Feb 2025)



CONNECTED EXPERTISE

BRIJ's rail, bus and pedestrian links connect inner-city and greater Brisbane talent pools

The planned 12-minute end-to-end underground rail service will connect the entire Brisbane Knowledge Corridor

Forecast to become Queensland's second-busiest bus and rail interchange

Pedestrian link between Boggo Road transport interchange and Princess Alexandra Hospital (PAH)

Dedicated bus link to The University of Queensland's St Lucia campus (3 mins), connecting TRI, PAH, Royal Brisbane and Women's Hospital, and Mater hospitals



SPECIALISED FACILITIES

\$100m+ translational manufacturing facility, ENTRI, under construction

Regulatory-compliant laboratories, including state-of-the-art bioengineering centre

Advanced controlled-environment greenhouses for optimised plant research

Labs with Physical Containment (PC1-PC3) facilities to support life sciences R&D

Drug development infrastructure including cGMP cleanrooms, pre-clinical labs and specialised Core Facilities



INTENTIONAL LEADERSHIP

Cross-partner governance aligns diverse organisational priorities for precinct benefit

Strategic leadership supports the merging of innovative ideas across healthcare and environmental sectors

Outcome-driven focus ensures resource optimisation

The Precinct Office fosters collaboration at local, national and international levels, providing guidance to companies seeking to establish themselves and secure investment



REAL-WORLD IMPACT

Over 100 years of continuous healthcare service and clinical innovation, supporting ~720k patients annually

Birthplace of Gardasil, the vaccine developed within The University of Queensland (UQ) that revolutionised cervical cancer prevention worldwide

Internationally recognised for multidisciplinary Phase I/II clinical trials, providing crucial validation pathways for therapeutic development

Globally certified manufacturing facilities for clinical and commercial biotherapeutics

Robust pipeline of early- and growth-stage biotech and biomedical companies



DISTINGUISHED PARTNERS

Home to world-renowned institutions leveraging advanced technologies at the unique intersection of planetary and human health, including:

- Translational Research Institute (TRI): a partnership between UQ, Queensland University of Technology (QUT), Mater Research and the Queensland Government
- UQ Dutton Park campus
- Princess Alexandra Hospital
- Ecosciences Precinct including CSIRO and Queensland Government
- Thermo Fisher Scientific
- Sanofi
- Flourishing ecosystem of small-to-medium startups and sector-supporting organisations



CAREER DESTINATION OF CHOICE

Global centre of excellence drawing experts in integrated health, agricultural and environmental research

10,000+ highly skilled workers and support staff on site, plus ~2700 students


Indoor-outdoor communal spaces leverage Brisbane's 300 days of sunshine per year

Beyond existing cafes, a planned retail village will provide convenient food options, everyday services and allied health facilities

Walkable precinct design promotes spontaneous interaction and knowledge exchange

Embedded education pathways with proximate schools and universities

FIRST NATIONS KNOWLEDGE GUIDES OUR PATH FORWARD



IMG: Boggo (also spelled Bloggo or Bolgo) is an Indigenous term referring to 'two leaning trees', a natural landmark that served as a traditional wayfinding marker.

We acknowledge the Traditional Owners of the land where Boggo Road Innovation Junction is located. We also acknowledge the many Aboriginal and Torres Strait Islander people from throughout Australia who now make the local area home and play an important role in the community.

Brisbane stands on the ancestral lands of the Yagara and Turrbal peoples, where ancient knowledge has been intrinsic to life for millennia. Here, BRIJ emerges as a meeting place where First Nations wisdom informs scientific progress.

Boggo has always been a place of healing, teaching and connection – a heritage we proudly acknowledge as we create new beginnings. BRIJ aims to be a safe and welcoming place for all, recognising that First Nations communities were the original doctors, scientists and innovators on this continent.

Working collaboratively with First Nations community members, we are fostering relationships focused on elevating traditional values and perspectives within BRIJ's design, research approach and governance.

This is our opportunity to engage with and learn from the oldest continuous culture in the world as we work towards true reconciliation between Indigenous and non-Indigenous people. Through mutual understanding and respect, we are creating new shared histories together as we stride towards an equitable society where we can reconnect with Country and draw from this profound heritage.



IMG: CSIRO's approach to education has demonstrated how integrating Aboriginal and Torres Strait Islander knowledge systems with mainstream scientific approaches creates a two-way learning model that enriches outcomes for all.



IMG: Collaborative research into native species like fingersop harnesses Queensland's unique biodiversity for future food security and innovation.

“This place has always held knowledge and voice. Since time immemorial, Country here has held our people through a partnership of care. That knowledge still exists here; it is in the very ground we walk on.”

— Local First Nations community member



QUEENSLAND: THE FUTURE UNFOLDS HERE

Queensland, Australia, has long been celebrated for its natural treasures – from the Great Barrier Reef and golden beaches to the ancient Daintree Rainforest and rugged outback. Now, the state's thriving knowledge economy is emerging as its next great asset, with Queensland's health, biomedical and earth sciences research cited more than three times the global average.¹

This success builds upon Queensland's well-established, highly collaborative academic and industry ecosystem, with scientific networks bridging the Asia-Pacific region and international research communities. The state's remarkable diversity of climates and ecosystems – from tropical rainforests to subtropical coastlines and vast grazing plains – connects local innovations to overseas markets, expanding their application and impact worldwide.

3x tier-1 universities

including QUT, Griffith and UQ (including QUT, Griffith, and UQ (a globally top 50 ranked institution²), offering access to elite research and talent

60% more cost-effective

clinical trials than the US thanks to Australia's 43.5% R&D Tax Incentive³, maximising investor capital efficiency and accelerating ROI timelines

~3x faster clinical trials

in Australia compared to the US and ~2x faster than the UK for Phase I studies, accelerating time-to-market for new therapeutics⁴

32 direct international connections

to Asia, Middle East, Oceania and North America, providing round-the-clock global market access via the Brisbane International Airport⁵

13th country in the world by GDP⁶

Australia's economic strength has supported Queensland's two decades of growth at rates surpassing the national average⁷

**A\$569m
A\$13.3bn**

Queensland biomedical exports⁸

Queensland agriculture and food exports (2023-24)⁹

43% higher health index returns

realised by Australian investment landscape versus US health stocks 2014-2024³

THE BRISBANE DIFFERENCE

81% startup ecosystem growth

characterised Brisbane's entrepreneurial landscape between 2019–2023, creating a wealth of investment targets and validating the region's innovation climate¹¹

19% population surge

predicted to 2032 – after 21% in the preceding period – cementing Brisbane as one of the nation's fastest growing capitals¹²

34% forecast economic growth

2021–2031¹³ putting Brisbane's economy on course to reach A\$275bn by 2041

5.4% annual health sector growth

from 2011–2021 outpaced Melbourne and Sydney, demonstrating Brisbane's proven model for healthcare investment¹⁴

36% projected health sector growth

over the decade to 2031, underpinned by Australia's highest per capita health R&D spend and a sector that has doubled to A\$22bn since 2010³

100+ health and biotech facilities


concentrated in Brisbane's core¹⁰ provide exceptional research density in a vibrant city environment attractive to high-calibre talent

2032 Olympic and Paralympic Games

host city rights secure Brisbane's status as a premier global destination, guaranteeing public investment, heightened international visibility and talent attraction

As Queensland's capital and a gateway to the Asia-Pacific, Brisbane offers companies a base of world-class talent and leading research institutions with working hours in step with global hubs such as Singapore, Hong Kong and Tokyo.

This advantageous position is strengthened by an A\$100.6bn Greater Brisbane major projects and infrastructure pipeline³ including port expansions, airport upgrades and the new Cross River Rail underground line.



Distinct lifestyle advantage

Year-round subtropical sunshine, a relaxed outdoor lifestyle and short commute times combine with affordable living to offer unmatched work-life balance.



World-class education & research

Brisbane's skilled workforce, mature innovation ecosystem and robust Intellectual Property protection provide a dependable base for commercialisation and scale, offering particular advantages for healthcare, environmental and biotech enterprises.



Brisbane Knowledge Corridor

A 5km knowledge corridor traverses Brisbane's CBD, strategically linking the southern hemisphere's largest concentration of research institutions, hospitals and industry partners through purpose-built rail connections, with BRIJ anchoring its southern end.



Premier innovation status

International indices such as the Innovation Cities Index¹⁵ and *Global Startup Ecosystem Report*¹¹ place Brisbane among the world's top 40, highlighting its dual strength in institutional innovation and emerging startup culture.


"Inspired by the best innovation models around the world, we are optimising Brisbane's scientific infrastructure to serve Queensland and address challenges far beyond our borders."

— Prof Kerrie Wilson, Queensland Chief Scientist


CONNECTED EXPERTISE

New underground rail and pedestrian links will soon reduce travel between BRIJ and Herston Health Precinct from 30 to 12 minutes¹⁶, accelerating collaboration across this highly networked research community.

TERTIARY EDUCATION		RESEARCH INSTITUTES & BIOMANUFACTURING	HOSPITALS & HEALTHCARE
01	The University of Queensland (St Lucia, Herston & Dutton Park campuses)	09 Ecosciences Precinct	18 Princess Alexandra Hospital
02	Griffith University (CBD Campus, Queensland College of Art and Design)	10 Translational Research Institute (TRI)	19 Mater Hospitals (Public, Private, Mothers', Children's)
03	QUT (Kelvin Grove & Gardens Point campuses)	11 ENTRI	20 Queensland Children's Hospital
04	University of the Sunshine Coast	12 QIMR Berghofer	21 Royal Brisbane and Women's Hospital, Stryker R&D Lab, Surgical Treatment and Rehabilitation Service (STARS)
05	Central Queensland University	13 Herston Imaging Research Facility	22 Greenslopes Hospital
06	James Cook University	14 Thermo Fisher Scientific – Patheon, Pharma Services Group	23 St Vincent's Private Hospital
07	University of Southern Queensland (CBD and South Bank campuses)	15 Centre for Children's Health Research	24 Brisbane Private Hospital
08	TAFE Queensland	16 Wesley Research Institute	25 St Andrew's War Memorial Hospital
		17 CSIRO eHealth Research Centre	26 The Wesley Hospital




WHERE GREAT MINDS MEET




At BRIJ, leading thinkers in human health and environmental science work side by side, creating a rare fusion that enables insights from planet and people to flow freely. This unique interplay, powered by cutting-edge technologies, sparks breakthroughs with transformative potential across multiple domains.

FOR PEOPLE AND PLANET



IMPACT AND INFLUENCE

Here are some of the ways the organisations within BRIJ are translating scientific curiosity into transformative solutions that shape our understanding of human and planetary health.



MERGING INSIGHTS, MULTIPLYING OUTCOMES

BRIJ's twin focus on improving lives and strengthening ecosystems, supported by enabling technologies, is underpinned by over 60 specialised research capabilities across critical domains including healthcare, biotech, medtech, agritech, environmental science and data analytics.

Here, clinicians developing mRNA vaccines work alongside agricultural researchers improving crop resilience, while data scientists collaborate with medical device innovators to create breakthrough diagnostic tools. This first-of-its-kind scientific convergence enables faster commercialisation of solutions addressing global health challenges, food security and environmental sustainability.

TIER 1 FLAGSHIPS
TIER 2 CORE CAPABILITIES
TIER 3 FULL CAPABILITIES



BRIJ ECOSYSTEM

BRIJ brings together top experts from academia, government and industry across biomedical innovation, clinical translation, environmental science, agricultural practices and quantum technologies to foster a dynamic community that welcomes new businesses and fresh perspectives.



DEPARTMENT OF PRIMARY INDUSTRIES (DPI)

- DPI ensures Queensland's primary industries are profitable, productive and sustainable. It works with industry, communities and government to grow the economy, strengthen rural regions, protect against biosecurity threats and guarantee long-term food, fibre, timber and renewable fuel security for Queensland and beyond.

DEPARTMENT OF ENVIRONMENT, TOURISM, SCIENCE AND INNOVATION (DETSI)

- DETSI delivers evidence-based science and policies for climate resilience, biodiversity and resource management while advancing sustainable tourism and research translation for economic and ecological benefit.

DEPARTMENT OF STATE DEVELOPMENT, INFRASTRUCTURE AND PLANNING (DSDIP)

- DSDIP coordinates Queensland's infrastructure strategy, promoting major projects, private sector investment and industry growth.

- HUMAN HEALTH & ENABLING TECHNOLOGY
- PLANETARY HEALTH & ENABLING TECHNOLOGY

QUEENSLAND CHIEF SCIENTIST (QCS)

- The QCS advises the state government on science research for policy decisions. As a high-profile figurehead for scientific capability, the role drives collaboration, supports research translation and engages with schools, industry and community while representing Queensland internationally.

QUEENSLAND HEALTH (QH)

- QH provides high-quality, accessible patient services statewide, partnering with TRI to transform research into clinical solutions that improve health outcomes for over 5 million Queenslanders, including at the Princess Alexandra Hospital (PAH) within BRIJ.

METRO SOUTH HOSPITAL AND HEALTH SERVICE (MSH)

- MSH oversees Brisbane's southern suburbs including PAH, a digital public healthcare hub driving medical innovation through collaboration with academia and industry.



COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION

- ● Australia's national science agency has developed more than 5000 patents and 150 spinouts. In BRIJ's Ecosciences Precinct, CSIRO teams pioneer environmental science, bioengineering and sustainable resource management among other critical research domains.



IMG: Hands-on expertise driving innovation at BRIJ.

BOGGO ROAD INNOVATION JUNCTION FACILITIES

From advanced clinical trial resources to specialised manufacturing facilities, BRIJ houses the infrastructure and equipment to turn concepts into commercial reality.

ECOSCIENCES PRECINCT (ESP)

- ● ESP is a 50,000sqm interdisciplinary research hub featuring PC1-3 labs, cGMP cleanrooms, CSIRO's BioFoundry, quarantine glasshouses, insectarium, a marine research fleet. Its purpose-built labs and collaboration spaces unite over 1000 scientists from state, federal and academic institutions including the Queensland Government, CSIRO and UQ.

PRINCESS ALEXANDRA HOSPITAL (PAH)

- A fully digital tertiary hospital, PAH enables world-first clinical trials through advanced infrastructure including its TRI Clinical Research Facility. It hosts the Australian Centre for Complex Integrated Surgical Solutions and early-adopted technologies such as the Gamma Knife® and Vectra body scanner.

↳ SECTION CONTINUES

BRIJ FACILITIES

TRI

- As an Australian-first initiative, TRI spearheads bench-to-bedside medical research, connecting scientists, clinicians and industry in a collaborative environment. Its world-class facilities encompass state-of-the-art labs equipped with preclinical imaging, flow cytometry for detailed cell analysis, histology for tissue examination, microscopy for cellular visualisation, gnotobiotics for germ-free research, humanised immune models for evaluating new treatments, and cleanrooms – all focused on translating research into improved healthcare outcomes.

ENTRI

- Opening in 2026, TRI's A\$100m+ facility will be Australia's first on-demand cGMP manufacturing hub for biotech, pharma and medtech companies. With on-site technical support, firms can scale manufacturing for Phase I-III clinical trials meeting global standards for biologics, RNA, cell therapies and more.

UQ SCHOOL OF PHARMACY

- The School of Pharmacy has operated from its custom-designed A\$10m facility opposite PAH since 2010, fostering industry and government partnerships that advance pharmaceutical sciences while creating a talent pipeline feeding directly into BRIJ's specialised workforce.

TRI TRANSLATIONAL RESEARCH INSTITUTE AUSTRALIA

TRANSLATIONAL RESEARCH INSTITUTE AUSTRALIA

- TRI stands as a global leader in translating research into improved healthcare. This unique partnership between UQ, QUT, QH and Mater Research has delivered powerful impact through its collaborative ecosystem since 2012.

TRI RESIDENTS INCLUDE



THE UNIVERSITY OF QUEENSLAND AUSTRALIA

THE UNIVERSITY OF QUEENSLAND (UQ)

- Ranked in the global top 50 and one of Australia's leading universities, UQ collaborates with more than 400 organisations on drug discovery, therapeutics, biotechnology, sustainability, agriculture, AI and quantum. Through partnerships with TRI, PAH and other hospitals, UQ progresses products from research through clinical trials.

ThermoFisher SCIENTIFIC

PATHEON BY THERMO FISHER SCIENTIFIC

- Operating next door to TRI, Patheon runs Australia's sole commercial-grade biologics facility, providing contract drug manufacturing services including cutting-edge mammalian cell cultivation, purification and contamination control.

mater research

MATER RESEARCH

- Established in 1998 to embed scientific discovery into patient care, Mater Research has spearheaded solutions in maternal health, cancer treatment, neuroscience and chronic disease management. With facilities at TRI, its teams collaborate with Mater Health and UQ to transform laboratory innovations into improved healthcare outcomes.

QUT Queensland University of Technology

QUEENSLAND UNIVERSITY OF TECHNOLOGY

- Counted among Australia's leading universities for commercialisation success, QUT translates research into market-ready health innovations. Through its integration with TRI, QUT combines talent development with translational research, building on Australia's highest rated biomedical engineering program and more than 100 active industry collaborations.

QIC

QUEENSLAND INVESTMENT CORPORATION

- A state-owned investment manager, QIC advises government while delivering real asset solutions across diverse sectors for around 120 global clients (A\$135.2bn AUM as at 30 September 2025). QIC plays a central role in BRIJ's leadership, acting as master developer for the precinct and its future expansion opportunities.

Translational Science Hub (TSH)

- The TSH connects Queensland researchers with Sanofi scientists in France and the US, forming a first-of-its-kind international collective focused on mRNA technology and translational medicine. Established in 2022, the collaboration unites Sanofi, UQ, Griffith University and the Queensland Government.

sanofi

SANOFI

- Sanofi is an innovative global healthcare company driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible.

Griffith UNIVERSITY

GRIFFITH UNIVERSITY

- Griffith University provides world-leading expertise in drug discovery, clinical trials and pharmaceutical sciences. Recognised in the top 2% of universities globally, Griffith advances new therapies through partnerships with industry, clinicians and research communities.

COLLECTIVE INTELLIGENCE

TURNING IMPOSSIBILITIES

INTO MARKET REALITY

GARDASIL: A BLUEPRINT FOR BRIJ'S MARKET POTENTIAL



REAL-WORLD IMPACT

270 million doses

administered in 130 countries²⁷

90% protection

against cervical cancer HPV strains
in next-generation vaccine²⁸

100,000 deaths prevented

2007–2023, according to conservative estimates²⁹

US\$58.8bn global sales

by Merck & Co between 2006–2024, making Gardasil
the company's second most successful product³⁰

The Gardasil vaccine exemplifies Australian research commercialisation at its finest and showcases the extraordinary investment returns possible at BRIJ.

Born in UQ laboratories on this very site, this technology has the potential to eradicate the world's fourth most common female cancer within a single generation – a market opportunity with profound human and economic impact.

Pioneered by Prof Ian Frazer AC and the late Dr. Jian Zhou at UQ's labs in the Diamantina Research Centre next to PAH in the 1990s, the human papillomavirus vaccine has prevented millions of cervical cancer cases worldwide since regulatory approval in 2006.³¹

Following intellectual property licensing to American drugmaker Merck & Co via Australian biotech firm CSL Limited, Australia led the wave of international adoption with a national HPV vaccination program. The results proved remarkable, including a 77% decrease in HPV infections among young women within five years.²⁹

In addition to lives saved, the vaccine has spared hundreds of thousands from invasive treatments while preserving their ability to fully participate in their careers, families and communities.

Inspired by Gardasil's impact, the Australian and Queensland governments partnered with Chuck Feeney's Atlantic Philanthropies to invest over A\$350m in establishing TRI under Frazer's leadership, creating a model that connects scientists, clinicians and industry under a bench-to-bedside philosophy. Today, the ~40,000sqm facility houses more than 1100 research scientists, medical practitioners and business professionals.

Broadening this vision, BRIJ addresses critical commercialisation barriers by providing clinical trial networks, regulatory expertise and industry partnerships that accelerate time-to-market. With Gardasil demonstrating how Queensland research can achieve global market penetration within 15 years of first laboratory findings, BRIJ offers investors early access to a pipeline of innovations with similar transformative potential.

The Gardasil story is not just history – it is the template for BRIJ's future.

“What took 18 months in the ‘90s can now be accomplished in just three days using the technologies at BRIJ.”

— Emeritus Prof Ian Frazer AC

TRANSLATING INSIGHTS

INTO
ACTION

Continuing a tradition of world-changing discoveries like Gardasil, here is a snapshot of active research-to-market journeys at BRIJ.



MICROBA™

UNLOCKING THE SECRETS
OF INNER HEALTH



Sector: Diagnostics
BRIJ location: TRI
Market opportunity: ~US\$1.4tn³²
Stage: In market

Microba Life Sciences, launched at TRI in 2018, pioneered advanced DNA analysis technology known as metagenomics for comprehensive gut microbiome profiling. This work has illuminated the complex relationships between micro-organisms and health, helping to advance personalised medicine.

Under the guidance of TRI ambassador Prof Ian Frazer AC and a team of microbiome experts, Microba developed the world's first accredited diagnostic test capable of detecting 175 gut pathogens in a single exam. This breakthrough attracted international healthcare partners for the global rollout of at-home gut health testing.

Following a successful A\$30m IPO in 2022, Microba continues to expand its gut analysis services while developing new treatments for autoimmune conditions. Research with the Australian Department of Defence further underscores the technology's broader potential.

Microbio

LEADING THE CHARGE
AGAINST SEPSIS



Sector: Biotech
BRIJ location: TRI
Market opportunity: ~US\$38.9bn³³
Stage: In market

QUT spinout Microbio has developed a breakthrough pathogen test transforming the detection of sepsis, a silent killer responsible for 11 million deaths annually worldwide.³⁴

Based at TRI, this biotech scale-up is pioneering blood testing with its InfectID products, which rapidly identify bacterial, fungal and viral infections. Every hour of delayed treatment increases sepsis mortality by 7.6%,³⁵ and InfectID-BSI detects blood-borne pathogens leading to sepsis and septic shock about 13 hours faster³⁶ than conventional methods. Particularly valuable in developing regions with limited healthcare infrastructure, Microbio's technology is already commercially available in Europe, the UK and India.

With A\$3.5m raised in 2022, the company is conducting clinical trials at BRIJ in pursuit of Australian and US regulatory approval, expanding its manufacturing capacity and exploring applications in water testing and veterinary diagnostics.

A PARADIGM SHIFT IN VACCINE DELIVERY



Sector: Biotech
BRIJ location: UQ
Market opportunity: ~US\$159bn by 2032³⁷
Staff: 160+
Stage: Clinical trials

Vaxxas is developing a needle-free patch with the potential to transform vaccination globally. The high-density microarray patch (HD-MAP) is made up of thousands of microprojections covered in tiny doses of vaccine, delivering it directly into the skin and triggering an immune response comparable to a traditional needle and syringe, but with a smaller dose.

Born from technology developed at UQ, Vaxxas joined TRI in 2015 to leverage its advanced infrastructure and industry support before relocating to a custom-built biomedical facility just over the river in 2023.

Since inception, the Brisbane biotech has secured over A\$250m in funding. Its latest private funding round will support Phase II and III clinical trials and manufacturing scale-up, positioning Vaxxas for its first commercial products and revenue generation from 2028.

ENGINEERING A WASTE-FREE FUTURE



Sector: Bioengineering
BRIJ location: CSIRO BioFoundry
Funding: 3-year project
Stage: In development

Global bioplastic production has doubled since 2010, yet to fully realise its environmental benefit and contribute to a circular economy, improved systems for bioplastic degradation and recycling must evolve.

To this end, CSIRO researchers are developing enzyme-based technologies that break bioplastic waste into its basic chemical components. The team uses computational genomics, machine learning and high-throughput testing to screen thousands of enzyme variants at the BioFoundry.

The work offers two solutions: embedding enzymes during production to ensure biodegradability, or using enhanced enzymes for recycling.

Its aim is to create enzymes that are highly active, ensuring an efficient, cost-effective process for large-scale recycling.

HEALING HEARTS WITH NATURE'S VENOM



Sector: Biotech
BRIJ location: TRI
Stage: In development

Infensa Bioscience is revolutionising treatments for heart attack and stroke – the world's leading causes of death – by converting spider venom into life-saving medicine. The breakthrough uses a peptide inspired by the K'gari funnel-web spider that blocks the signal prompting oxygen-starved cells to die during cardiac events.

After securing A\$23m and licensing research from UQ's Institute for Molecular Bioscience, Infensa joined TRI in 2022 to develop what could become the world's first cardioprotective drug. With government-funded human trials underway in 2025, this innovation aims to transform emergency cardiac care by improving survival rates and extending donor heart viability during transplantation.

TACKLING A HIDDEN REPRODUCTIVE RISK



Sector: Biotech
BRIJ location: TRI
Stage: Clinical trials

A world-first chlamydia vaccine is being developed through the A\$280m Translational Science Hub, a collaborative venture joining Sanofi with UQ and Griffith University alongside the Queensland Government.

The initiative addresses Australia's most common sexually transmitted infection, which surged 24% between 2021 and 2023³⁸ and is linked to chronic pain and fertility issues. Unlike antibiotics, the vaccine candidate provides protection against primary infection and reinfection.

By connecting local researchers to 600 Sanofi scientists at mRNA Center of Excellence bases in the US and France, this groundbreaking project is set to strengthen Queensland's capabilities in vaccine manufacturing and preventative healthcare innovation.

THE FIRST STEP

IN OUR BOLD AMBITION

The BRIJ masterplan merges research spaces, educational facilities, vital healthcare services, corporate headquarters, incubator hubs, everyday retail conveniences and public courtyards into a dynamic environment where complementary knowledge intersects.



PLANNING FOR FUTURE GROWTH

Our long-term vision unlocks a sequence of pivotal developments to significantly expand BRIJ's talent pool and translation infrastructure.



Artist impression

● **Yamma Bridge** links the two halves of the precinct, providing seamless pedestrian and cycling access to public transport options while thoughtful landscaping and seating promote a calmer, more comfortable journey for active commuters.



Artist impression

● **A\$10bn in transit and infrastructure upgrades** – including new underground rail, overground services and electric buses – converge at the tri-modal Boggo Road interchange, improving commuter access and strengthening connections to the CBD.



Artist impression

● The two-level **Boggo Road Village retail centre** will bolster everyday convenience for BRIJ staff and visitors with its supermarket, casual dining options, specialty retail and allied health services, while fostering community interaction.



Artist impression

● **Princess Alexandra Hospital's A\$748m+ expansion** includes a four-storey addition to the Emergency Department, delivering more acute inpatient and ICU beds as well as new cancer treatment bays and enhanced kidney disease services.



● The envisioned **adaptive reuse of heritage-listed Boggo Road Gaol** seeks to honour the site's complex history while repurposing it as a forward-looking civic asset, presenting a major opportunity for legacy-sensitive urban renewal.



Artist impression

● **100,000sqm expansion** opportunity envisions lab-equipped offices with A-grade amenities, landscaped open areas and doorstep connectivity to public transport, shaping a place that draws world-class talent and sparks collaboration across sectors.

A NEW LANDMARK FOR MEDICAL MANUFACTURING

The Translational Research Institute's new manufacturing facility, ENTRI, is a game-changer for healthcare innovation in Australia.


Opening in 2026, ENTRI will be Australia's first on-demand production centre meeting rigorous cGMP standards for therapeutic products, enabling biotech, pharmaceutical and healthcare technology companies to accelerate development of next-generation treatments and devices.

Medical-grade cleanrooms, PC2-certified wetlabs and purpose-built office space are designed to enable growing companies to conduct their own manufacturing, quality testing and product development in one location. Supported by in-house technical experts and comprehensive training programs, these firms can seamlessly scale production across Phase I-III clinical trials while ensuring compliance with Australian and international regulation.

This transformative infrastructure at BRIJ removes a critical bottleneck in Australia's commercialisation pathway, allowing innovators to advance promising discoveries – from biologics and cell-based treatments to RNA and plasmid DNA therapies – through clinical validation and into patient care with unprecedented speed and confidence.



COMPLETES TRI'S EVOLUTION INTO ONE OF AUSTRALIA'S LARGEST INTEGRATED TRANSLATIONAL RESEARCH COMPLEXES



ADDS 7000SQM OF SPECIALISED FLOORSPACE ACROSS FOUR STOREYS




A \$100M+ INVESTMENT BY THE QUEENSLAND GOVERNMENT AND TRI



STRONG PRE-OPENING OCCUPANCY INTEREST



PROJECTED TO CREATE 500 HIGHLY SKILLED SCIENCE JOBS AT CAPACITY



SERVICES

QUALITY MANAGEMENT

Expert quality assurance team ensuring product safety, regulatory compliance and continuous improvement.

MATERIALS HANDLING

Comprehensive management of raw materials, incoming goods and final products, including disposition and specialised storage from room temperature to ultra-cold and cryogenic conditions.

EQUIPMENT LIFECYCLE OVERSIGHT


End-to-end support for equipment implementation, commissioning, qualification, validation, calibration and maintenance.

FACILITY SERVICES

Facility cleaning (including autoclave sterilisation), environmental monitoring and waste management.

OPERATIONAL SUPPORT

Supply chain and logistics management, plus cGMP compliance consulting and training.



IMG: TRI's biophilic design embraces Brisbane's subtropical climate.



IMG: Open-air communal spaces at TRI inspire productive exchanges.

“Great design is a value creator because great places don't just attract talent—they inspire it. BRIJ is where ideas ignite.”

— Dr Kate Meyrick, Urbis



IMG: Thoughtful architecture enhances both wellbeing and creativity.

DESIGNED FOR CONNECTIVITY

INSPIRING TALENT, EXPANDING HORIZONS

BRIJ's design prioritises human connection, creating environments that empower exceptional minds to solve society's biggest challenges.

Modelled on learnings from global centres of innovation, BRIJ's design philosophy recognises the power of place, and the importance of harmonious workspaces for human wellbeing, satisfaction and performance. Here, thoughtfully planned layouts prioritise walkability and ground-level connectivity, encouraging fluid movement that brings people together. Interconnected pathways create natural meeting points for spontaneous interaction, while abundant natural light, integrated greenery and strategic gathering areas enhance creativity and teamwork.

Urban studies research demonstrates that strategically integrating formal workspaces with informal social hubs fosters innovation by enabling cross-disciplinary exchanges that build trust and reduce siloed expertise.³⁹

Leveraging the benefits of the co-located critical mass of research entities, our masterplan fosters environments that attract specialised talent and accelerate innovation through seamless knowledge-sharing and collaborative problem-solving. Integration of nature, neighbourhood amenities, cultural elements and social gathering spaces also combine to form a vibrant, multi-purpose setting.

This emphasis on quality of place gives resident organisations a compelling advantage in the worldwide competition for elite researchers and technical specialists. By focusing on the social dimensions that drive innovation, BRIJ creates an atmosphere where ideas ignite and groundbreaking achievements take shape.



ENHANCED BIODIVERSITY & NATIVE PLANTINGS



WALKABLE DESIGN ENCOURAGES MOVEMENT & INTERACTION



WELCOMING SPACES THAT FOSTER BELONGING



CULTURAL HERITAGE EMBEDDED IN PLACE



ENERGY-SMART GREEN DESIGN



HIGH-PERFORMANCE WORKPLACES

OUR LONG-TERM VISION

FOR SHARED SUCCESS

Our mission is to create a magnetic destination that redefines the modern innovation precinct, where superior liveability and work-life balance set new benchmarks while evolving with the aspirations of future generations.

INTENTIONAL LEADERSHIP

An expert-led governance framework designed to foster cross-disciplinary collaboration, inclusion and a vision for sustainable innovation.

BRIJ's strategic direction sits in experienced hands, with governance led by a nine-strong council of representatives from organisations spanning biomedical enterprise, healthcare management, public sector leadership and institutional investment.

This group brings together hospital and health service directors, company executives and senior representatives from government and academia, complemented by First Nations cultural advisers and development specialists. Their unified focus is to deliver commercial outcomes and life-saving advances in fields connecting human and environmental health.

The council's strong track record in industry engagement and precinct development underpins BRIJ's mission to attract global scientific talent and trailblazing enterprises. Priorities include accelerating business involvement, fostering career pathways and creating the optimal conditions for both multinationals and high-growth startups to thrive.

It is a governance framework designed for both tangible market impact and sustainable long-term value creation at the nexus of human and planetary wellbeing.

PRECINCT OFFICE

The Precinct Office seeks to drive the success of BRIJ occupants through effective market positioning, investment attraction and streamlined pathways to commercialisation removing barriers to commercialisation. Working with industry leaders, state development strategists, professional associations, healthcare practitioners, academic experts, innovation facilitators and BRIJ ambassadors, the Precinct Office aims to deliver targeted programs and valuable connections that fast-track scientific discoveries toward market viability and societal benefit.

OUR COMMITMENTS

INDIGENOUS ENGAGEMENT

Honour Queensland's original scientists, integrating their sophisticated understanding of Country.

GLOBAL-LOCAL IMPACT

Share BRIJ innovations with the world while drawing strength from Queensland's unique context.

TALENT DEVELOPMENT

Create direct pathways between education and industry for tomorrow's innovators.

SUSTAINABLE INFRASTRUCTURE

Embed environmental sustainability and climate resilience in everything we build.

JOBS & INDUSTRY ATTRACTION

Elevate Queensland as an R&D destination that delivers high-skill employment opportunities and fuels the knowledge economy.

PRECINCT COUNCIL

The Precinct Council establishes vision and strategic direction for the Precinct Office.



SECURE THE BRIJ ADVANTAGE

As BRIJ enters its next phase of growth, now is the ideal time to engage with Queensland's fastest-growing centre for translational science.

We welcome discussions with potential partners interested in research collaborations, industry expansion, laboratory and office leasing, institutional real estate investment, clinical trials, incubator or accelerator opportunities, venture capital deployment, access to specialist infrastructure and networking across our innovation ecosystem.



RESEARCH PARTNERSHIPS


Discover opportunities to work directly with world-class research teams at BRIJ.

Whether your interest lies in therapeutics, bioengineering, quantum computing or robotics, our partnership models provide early access to emerging technologies and market opportunities.



BUILD-OUT PIPELINE

For property and institutional investors, BRIJ offers a potential pipeline of health and life science developments in the state's most established innovation ecosystem.



CAPITAL & VENTURES

Position your capital to identify and invest in tomorrow's success stories.

We connect forward-thinking partners with promising ventures, providing deep sector expertise in transforming laboratory discoveries into commercial successes.



ADVANCED FACILITIES

Boost your research potential through flexible access to state-of-the-art laboratories and technical facilities.

Scale your R&D operations without the capital burden of building your own infrastructure, with options from project-based collaboration to long-term partnerships.



INVESTMENT INCENTIVES

Benefit from comprehensive government incentives including R&D tax rebates of up to 43.5%⁴. Australia's pro-business environment and strategic research agenda direct public funding to critical areas – vaccine development, advanced manufacturing and quantum technology among them.

BRIJ enhances collaborators' funding applications through direct assistance and the credibility gained from co-location in one of Australia's most respected knowledge centres.

YOUR NEXT BREAKTHROUGH BEGINS HERE

Whether you are exploring emerging technologies,
seeking meaningful partnerships, or looking to
advance the frontiers of human and planetary wellbeing,
we invite you to join the conversation.

CONTACT US

Prof Trent Munro
BRIJ General Manager

E trent@brij.au
T +61 499 880 791

W brij.au
LI linkedin.com/company/brij-au

SOURCES

WHY QUEENSLAND (p12)

- 1 Office of the Queensland Chief Scientist, Feb 2025
- 2 topuniversities.com/universities/university-queensland, Jun 2025
- 3 Brisbane Economic Development Agency (BEDA) *State of the City Report*, August 2025
- 4 statedevelopment.qld.gov.au/team-qld/clinical-trials, Jul 2024
- 5 bne.com.au, Feb 2025
- 6 ATIC *Why Australia Benchmark Report*, 2024
- 7 TIQ *Invest in Queensland* prospectus, Nov 2024
- 8 statedevelopment.qld.gov.au/industry/critical-industry-support/biomedical, May 2025
- 9 daf.qld.gov.au/news-media/campaigns/data-farm/export-trade, Sep 2024

WHY BRISBANE (p14)

- 10 BEDA, March 2024
- 11 *2024 Global Startup Ecosystem Report*
- 12 Population projections for major capital cities (2022-base to 2071), ABS 2023
- 13 10-year real growth forecast (2021-2031), *BEDA State of the City Report*, August 2025
- 14 *The Queensland Health and Hospitals Plan*, 2024
- 15 Innovation Cities Index 2022-23

BRISBANE KNOWLEDGE CORRIDOR (p16)

- 16 Cross River Rail Delivery Authority, 2024

VITAL STATISTICS (p22)

- 17 Estimated collective investment UQ, QUT, DPI, DETSI, TRI, CSIRO and PAH, Feb 2025
- 18 Based on publicly available revenue data for TRI partners, including Gardasil sales, using March 2025 exchange rates
- 19 Estimated collective revenue DPI and UQ, Feb 2025
- 20 PAH, ESP, UQ, TRI and Thermo Fisher Scientific
- 21 UQ, QUT and Griffith/ACU
- 22 Including PAH facilities
- 23 UQ, TRI and QUT spinouts
- 24 PAH, Feb 2025
- 25 UQ, TRI and QUT, Feb 2025
- 26 SciVal citations 2022–2024, Dec 2024

REAL-WORLD IMPACT

GARDASIL: A BLUEPRINT FOR BRIJ'S MARKET POTENTIAL (p32)

- 27 WHO *Weekly Epidemiological Record*, Jul 2017
- 28 cancercouncil.com.au/news/australian-success-story-hpv-vaccine, 2017
- 29 Philanthropy Australia, Nov 2023
- 30 Merck FY24 Results
- 31 cancer.org.au/about-us/how-we-help/research/stories/helping-australia-eliminate-cervical-cancer, Mar 2025

MICROBA (p35)

- 32 Total addressable market based on desktop study of microbiome-related disease patients in US, UK, AU, FR, DE, ES and IT with conservative USD pricing, Microba Life Sciences Q3 FY 2025 Investor Report.

MICROBIO (p35)

- 33 Total addressable market, Microbio Q2 FY 2025 Investment Memorandum
- 34 WHO *Global Report on the Epidemiology and Burden of Sepsis*, Sept 2020
- 35 *American Journal of Respiratory and Critical Care Medicine*, Oct 2017
- 36 *Journal of Microbiological Methods*, Aug 2023

VAXXAS (p36)

- 37 Global vaccine market value projection, *Fortune Business Insights*, April 2025

TRANSLATIONAL SCIENCE HUB (p37)

- 38 *National Notifiable Diseases Surveillance System*, 2023

INSPIRING TALENT, EXPANDING HORIZONS (p47)

- 40 *Conceptual frameworks of innovation district place quality*, Esmaeilpoorarabi et al, 2020

The Boggo Road Junction Council is currently facilitated by QIC Limited (ACN 130 539 123) as trustee for the Debt Retirement Trust and CRR Boggo Road Pty Ltd (ACN 659 848 665) as trustee for the Boggo Road Trust (QIC) and consists of QIC, the State of Queensland (represented by the Department of State Development, Infrastructure and Planning, Department of the Environment, Tourism, Science and Innovation, Queensland Health and the Department of Primary Industries), Metro South Hospital and Health Service, CSIRO, The University of Queensland, Translational Research Institute (the BRPC). The BRPC are connected in some way to the Boggo Road Innovation Junction and so are other independent entities which do not form part of the BRPC. The information in this document (the "Information") is general information only and this document is provided solely for general information purposes. The Information does not constitute advice of any nature and it has been prepared without purporting to contain all the information that a person considering the Information may require in using or evaluating it, and you should not rely on it for any reason. In preparing this Information the BRPC, their subsidiaries, associated entities, and their directors, employees, agents and representatives (the "BRPC Parties") have not taken into account the objectives, financial situation, circumstances or needs of any potential recipient of it. Some statements in the Information are based on information and research published by others. No BRPC Party has confirmed, and the BRPC does not warrant, the accuracy or completeness of such statements. Plans, drawings, photographs and illustrations are indicative only. The BRPC reserves the right to change any part of this document or the Information without notice. The Information may include statements and estimates in relation to future matters, many of which are based on subjective judgements or proprietary internal modelling. No representation is made that any such statements or estimates will prove correct. Past performance is not a reliable indicator of future performance. Forecast results may differ materially from results ultimately achieved. You should be aware that the Information may be predictive in character and may be affected by inaccurate assumptions and/or by known or unknown risks and uncertainties. You should seek your own independent advice and make your own independent investigations and assessment, in relation to the Information including before entering into a lease. This document does not constitute an offer document in respect of any premises or space. Neither this document nor anything contained in it nor any document in connection with it will form the basis of any contract or any obligation of any kind whatsoever. No such contract or obligation will be formed until all relevant parties execute a written contract. To the maximum extent permitted by law the BRPC Parties disclaim all responsibility and liability for any loss or damage of any nature whatsoever which may be suffered by any person directly or indirectly through the provision to, or use by you of the information contained in this document, whether that loss or damage is caused by any fault or negligence of the BRPC Parties or otherwise. This document and the Information is the property of QIC. QIC reserves the right to change any of this document or the Information without notice. All rights are reserved. Do not copy, disseminate or use, except in accordance with the prior written consent of QIC.

As at Feb 2026.



BOGGO ROAD INNOVATION JUNCTION

